卵巢癌是死亡率最高的妇科恶性肿瘤之一。卵巢癌干细胞（CSC）是卵巢癌细胞的一个亚群，具有增强的自我更新能力、攻击性、转移潜力以及对传统抗癌治疗的抵抗力。卵巢CSC的出现是卵巢癌患者治疗抵抗和频繁复发的关键因素，导致临床结果不佳。 MicroRNA (miRNA) 是一种短的非蛋白质编码 RNA，可调节卵巢 CSC 的发育。尽管多篇原创研究文章讨论了不同 miRNA 在卵巢癌中的 CSC 调节作用，但缺乏一篇综述文章来总结不同研究论文的发现。为了缩小文献中的差距，本综述旨在提供各种 miRNA 在调节卵巢癌细胞干性中的 CSC 调节作用的最新总结。本综述首先概述卵巢 CSC 以及驱动其出现的途径。接下来，将讨论 miRNA 在控制卵巢 CSC 发育中的 CSC 调节作用。总体而言，据报道有 60 多种 miRNA 在卵巢癌的发生和进展中发挥 CSC 调节作用。通过靶向各种下游靶标，这些 miRNA 可以控制 PI3K/AKT、EGFR/ERK、WNT/ß-catenin、NF-kß、Notch、Hippo/YAP、EMT 和 DNA 修复途径的信号传导活动。因此，这些 CSC 调节 miRNA 有潜力用作预测卵巢癌患者临床结果的预后生物标志物。靶向促进 CSC 的 miRNA 或增加抑制 CSC 的 miRNA 的表达可以帮助减缓卵巢癌的进展。然而，必须进行更深入的功能和临床试验来评估这些 CSC 调节 miRNA 作为预后生物标志物或治疗靶标的适用性、安全性、敏感性和特异性。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Ovarian cancer is one of the gynaecology malignancies with the highest mortality rate. Ovarian cancer stem cell (CSC) is a subpopulation of ovarian cancer cells with increased self-renewability, aggression, metastatic potentials, and resistance to conventional anti-cancer therapy. The emergence of ovarian CSC is a critical factor that promotes treatment resistance and frequent relapse among ovarian cancer patients, leading to poor clinical outcomes. MicroRNA (miRNA) is a short, non-protein-coding RNA that regulates ovarian CSC development. Although multiple original research articles have discussed the CSC-regulatory roles of different miRNAs in ovarian cancer, there is a deficiency of a review article that can summarize the findings from different research papers. To narrow the gap in the literature, this review aimed to provide an up-to-date summary of the CSC-regulatory roles of various miRNAs in modulating ovarian cancer cell stemness. This review will begin by giving an overview of ovarian CSC and the pathways responsible for driving its appearance. Next, the CSC-regulatory roles of miRNAs in controlling ovarian CSC development will be discussed. Overall, more than 60 miRNAs have been reported to play CSC-regulatory roles in the development and progression of ovarian cancer. By targeting various downstream targets, these miRNAs can control the signaling activities of PI3K/AKT, EGFR/ERK, WNT/ß-catenin, NF-kß, Notch, Hippo/YAP, EMT, and DNA repair pathways. Hence, these CSC-modulatory miRNAs have the potential to be used as prognostic biomarkers in predicting the clinical outcomes of ovarian cancer patients. Targeting CSC-promoting miRNAs or increasing the expressions of CSC-repressing miRNAs can help slow ovarian cancer progression. However, more in-depth functional and clinical trials must be carried out to evaluate the suitability, safety, sensitivity, and specificity of these CSC-regulating miRNAs as prognostic biomarkers or therapeutic targets.Copyright © 2024 Elsevier B.V. All rights reserved.